Pathology

Reading Your Pathology Report

At a Glance

An MPNST pathology report provides critical details about your tumor's aggressiveness and diagnosis. Key elements include the FNCLCC grade, H3K27me3 marker loss confirmation, and surgical margin status. Always have your report reviewed by a specialized sarcoma pathologist at a major cancer center.

Your pathology report is the most important document in your medical file. It is the result of a pathologist examining your tumor tissue under a microscope and performing specialized chemical tests to confirm the diagnosis ^[1]. Understanding these terms will help you ensure your report is complete and accurate.

The FNCLCC Grading System

Pathologists use the FNCLCC system to determine how “aggressive” a sarcoma is. They assign scores in three categories ^[2]^[3]:

Tumor Differentiation (Score 1–3): How much the cancer cells look like normal nerve cells. A higher score means the cells look more abnormal ^[2].
Mitotic Count (Score 1–3): This measures how many cells are actively dividing. High numbers indicate a faster-growing tumor ^[3].
Tumor Necrosis (Score 0–2): This measures how much of the tumor is made of dead or dying tissue. More necrosis often points to a more aggressive tumor ^[4].

These scores are added together to give a Grade (1, 2, or 3). Most MPNSTs are considered high-grade (Grade 2 or 3). It is worth noting that a Grade 1 (low-grade) MPNST is exceptionally rare; the vast majority are high-grade ^[5].

Key Immunohistochemistry (IHC) Markers

IHC tests use special dyes to “stain” proteins in the cells. In an MPNST report, you will likely see:

H3K27me3 Loss: This is a hallmark of MPNST. A “complete loss” of this marker is found in about 80% of high-grade cases and helps confirm it is not a less aggressive tumor ^[6]^[7].
S100 and SOX10: These are markers of nerve cells. In MPNST, these are often focal (only in small spots) or completely absent, which helps distinguish it from benign nerve tumors ^[6]^[8].
Ki-67 Index: This is expressed as a percentage. It shows what proportion of the cancer cells are currently growing. A higher Ki-67 percentage (e.g., >30%) generally indicates a more aggressive growth pattern.

Understanding Surgical Margins

If you have had surgery, the report will describe the resection margins—the edge of the tissue the surgeon removed ^[9]:

R0 (Negative Margin): No cancer cells were found at the very edge of the removed tissue. This is the “gold standard” ^[10].
R1 (Microscopic Positive): The tumor was removed, but cancer cells are visible at the edge under a microscope ^[11].
R2 (Macroscopic Positive): The surgeon could see that some tumor was left behind during the operation.

Pathology Completeness Checklist

A high-quality MPNST pathology report should include the following ^[12]^[13]:

[ ] Final Diagnosis: Clearly stating Malignant Peripheral Nerve Sheath Tumor.
[ ] Tumor Size: Maximum diameter in centimeters.
[ ] FNCLCC Grade: Including the individual scores for mitosis and necrosis.
[ ] Margin Status: Stated as R0, R1, or R2, ideally with the distance in millimeters to the closest edge.
[ ] IHC Panel: Results for H3K27me3, S100, and SOX10 at a minimum.
[ ] Lymph Vascular Invasion: Whether the tumor has started to enter local blood or lymph vessels.

If your report is missing these details, or if you were diagnosed by a general pathologist, it is standard practice to request a review by a specialized sarcoma pathologist at a major cancer center ^[14].

Common questions in this guide

What does the FNCLCC grade mean on my MPNST pathology report?

The FNCLCC system grades how aggressive a sarcoma is by scoring tumor differentiation, mitotic count, and tumor necrosis. These scores are combined to assign a final grade of 1, 2, or 3. Most malignant peripheral nerve sheath tumors are considered high-grade, which means Grade 2 or 3.

What does a complete loss of H3K27me3 mean?

A complete loss of the H3K27me3 marker is a hallmark sign found in about 80% of high-grade MPNST cases. Pathologists use this specific immunohistochemistry test to help confirm your diagnosis and distinguish your tumor from other, less aggressive nerve tumors.

What is the difference between R0, R1, and R2 surgical margins?

These terms describe whether cancer cells were left behind after surgery. An R0 margin means no cancer cells were found at the edge of the removed tissue, which is the best outcome. R1 means microscopic cancer cells were visible at the edge, and R2 means visible tumor was left behind.

Why is the Ki-67 index important in my report?

The Ki-67 index is a percentage that shows how many of the cancer cells are currently actively dividing and growing. A higher percentage generally indicates that the tumor has a more aggressive and rapid growth pattern.

Should I get a second opinion on my MPNST pathology report?

Because malignant peripheral nerve sheath tumors are rare and complex, it is standard practice to have your pathology report reviewed by a specialized sarcoma pathologist. If you were diagnosed by a general pathologist, asking your doctor to send your tissue to a major cancer center for a second opinion is highly recommended.

Curated prompts to bring to your next appointment.

1.What was the exact 'mitotic count' in my report, and how does that affect the tumor's grade?
2.Was there a complete or partial loss of H3K27me3, and how certain are you that this rules out other similar cancers?
3.What is the distance of the 'closest' surgical margin in millimeters?
4.Was my pathology reviewed by a specialized sarcoma pathologist? If not, can we send it for a second opinion?
5.Does my tumor show any 'necrosis' (dead tissue), and if so, what percentage of the tumor was affected?

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References (14)

1
Cellular Schwannoma of the Palate Simulating as Malignant Peripheral Nerve Sheath Tumor: A Diagnostic Marathon.
Bajpai M, Mani A, L Sabnis S, Rani Rm V
Journal of dentistry (Shiraz, Iran) 2024; (25(4)):383-387 doi:10.30476/dentjods.2024.101035.2265.
PMID: 39713108
2
Leiomyosarcoma FNCLCC G3 pT2B of broad ligament adherent to right oviduct - case report with molecular profiling.
Wincewicz A, Kowalik A, Zięba S, et al.
Romanian journal of morphology and embryology = Revue roumaine de morphologie et embryologie 2016; (57(4)):1409-1414.
PMID: 28174812
3
Histopathological Spectrum of Soft-Tissue Tumors with Immunohistochemistry Correlation and FNCLCC grading: A North Indian Experience.
Singh HP, Grover S, Garg B, Sood N
Nigerian medical journal : journal of the Nigeria Medical Association 2017; (58(5)):149-155 doi:10.4103/nmj.NMJ_226_16.
PMID: 31198267
4
Federation Nationale des Centers de Lutte Contre le Cancer grading of soft tissue sarcomas on needle core biopsies using surrogate markers.
Lin X, Davion S, Bertsch EC, et al.
Human pathology 2016; (56()):147-54.
PMID: 27346575
5
Fédération Nationale Des Centres de Lutte Contre Le Cancer (FNCLCC) Grading, Margin Status and Tumor Location Associate With Survival Outcomes in Malignant Peripheral Nerve Sheath Tumors.
Wakeman KM, Zhang QS, Bandhlish A, et al.
American journal of clinical oncology 2022; (45(1)):28-35 doi:10.1097/COC.0000000000000877.
PMID: 34962906
6
Loss of H3K27 trimethylation distinguishes malignant peripheral nerve sheath tumors from histologic mimics.
Schaefer IM, Fletcher CD, Hornick JL
Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc 2016; (29(1)):4-13 doi:10.1038/modpathol.2015.134.
PMID: 26585554
7
H3K27me3 immunohistochemistry highlights the inactivated X chromosome (Xi) and predicts sex in non-neoplastic tissues.
Schaefer IM, Minkovsky A, Hornick JL
Histopathology 2016; (69(4)):702-4 doi:10.1111/his.12972.
PMID: 27306961
8
S100-negative epithelioid malignant peripheral nerve sheath tumor with possible perineurial differentiation.
Yamashita K, Funauchi Y, Hayakawa K, et al.
Virchows Archiv : an international journal of pathology 2022; (480(6)):1269-1275 doi:10.1007/s00428-021-03218-y.
PMID: 34635937
9
The Role of Plastic Reconstructive Surgery in Surgical Therapy of Soft Tissue Sarcomas.
Götzl R, Sterzinger S, Arkudas A, et al.
Cancers 2020; (12(12)) doi:10.3390/cancers12123534.
PMID: 33256182
10
Malignant peripheral nerve sheath tumors - Outcomes and prognostic factors based on the reference center experience.
Sobczuk P, Teterycz P, Czarnecka AM, et al.
Surgical oncology 2020; (35()):276-284 doi:10.1016/j.suronc.2020.09.011.
PMID: 32949967
11
Local recurrence rates of superficial versus deep soft tissue sarcoma.
Lin JS, Coleman L, Voskuil RT, et al.
Archives of orthopaedic and trauma surgery 2024; (144(7)):2967-2973 doi:10.1007/s00402-024-05326-1.
PMID: 38850420
12
Assessing the Utility of DNA Methylation Profiling in the Classification of Myogenic Sarcomas of Bone.
Bandhlish A, Liu YJ, Fang H, et al.
International journal of surgical pathology 2025; (33(5)):1103-1115 doi:10.1177/10668969241300497.
PMID: 39763459
13
Malignant Nerve Sheath Tumour - A Case Report.
Majitha CS, Pillai S, Shetty S, et al.
Indian journal of otolaryngology and head and neck surgery : official publication of the Association of Otolaryngologists of India 2024; (76(4)):3511-3518 doi:10.1007/s12070-024-04591-1.
PMID: 39130315
14
Limited biopsies of soft tissue tumors: the contemporary role of immunohistochemistry and molecular diagnostics.
Hornick JL
Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc 2019; (32(Suppl 1)):27-37 doi:10.1038/s41379-018-0139-y.
PMID: 30600320

This page explains MPNST pathology terminology for educational purposes. Your sarcoma pathologist and oncologist are the best sources for interpreting your specific lab results and guiding your care.

Get notified when new evidence is published on Malignant peripheral nerve sheath tumor.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

Guide Contents